Literature DB >> 22528455

PACAP is an endogenous protective factor-insights from PACAP-deficient mice.

D Reglodi1, P Kiss, K Szabadfi, T Atlasz, R Gabriel, G Horvath, P Szakaly, B Sandor, A Lubics, E Laszlo, J Farkas, A Matkovits, R Brubel, H Hashimoto, A Ferencz, A Vincze, Z Helyes, L Welke, A Lakatos, A Tamas.   

Abstract

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a widespread neuropeptide with a diverse array of biological functions. Not surprisingly, the lack of endogenous PACAP therefore results in a variety of abnormalities. One of the important effects of PACAP is its neuroprotective and general cytoprotective role. PACAP protects neurons and other tissues against ischemic, toxic, and traumatic lesions. Data obtained from PACAP-deficient mice provide evidence that endogenous PACAP also has protective functions. Mice lacking PACAP are more vulnerable to different in vitro and in vivo insults. The present review summarizes data on the increased sensitivity of PACAP-deficient mice against harmful stimuli. Mice lacking PACAP respond with a higher degree of injury in cerebral ischemia, autoimmune encephalomyelitis, and axonal lesion. Retinal ischemic and excitotoxic injuries also produce increased cell loss in PACAP-deficient mice. In peripheral organs, kidney cell cultures from PACAP-deficient mice are more sensitive to oxidative stress and in vitro hypoxia. In vivo, PACAP-deficient mice have a negative histological outcome and altered cytokine response in kidney and small intestine ischemia/reperfusion injury. Large intestinal inflammation, toxic lesion of the pancreas, and doxorubicin-induced cardiomyopathy are also more severe with a lack of endogenous PACAP. Finally, an increased inflammatory response has been described in subacute endotoxin-induced airway inflammation and in an oxazolone-induced allergic contact dermatitis model. In summary, lack of endogenous PACAP leads to higher vulnerability in a number of injuries in the nervous system and peripheral organs, supporting the hypothesis that PACAP is part of the endogenous cytoprotective machinery.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22528455     DOI: 10.1007/s12031-012-9762-0

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  85 in total

1.  Role of endogenous pituitary adenylate cyclase-activating polypeptide in adult hippocampal neurogenesis.

Authors:  Y Ago; M Yoneyama; T Ishihama; S Kataoka; K Kawada; T Tanaka; K Ogita; N Shintani; H Hashimoto; A Baba; K Takuma; T Matsuda
Journal:  Neuroscience       Date:  2010-10-23       Impact factor: 3.590

2.  Pituitary adenylate cyclase-activating peptide is upregulated in sensory neurons by inflammation.

Authors:  Y Zhang; N Danielsen; F Sundler; H Mulder
Journal:  Neuroreport       Date:  1998-08-24       Impact factor: 1.837

3.  Endogenous PACAP acts as a stress response peptide to protect cerebellar neurons from ethanol or oxidative insult.

Authors:  David Vaudry; Carol Hamelink; Ruslan Damadzic; Robert L Eskay; Bruno Gonzalez; Lee E Eiden
Journal:  Peptides       Date:  2005-07-11       Impact factor: 3.750

4.  Pituitary adenylate cyclase-activating polypeptide plays an anti-inflammatory role in endotoxin-induced airway inflammation: in vivo study with gene-deleted mice.

Authors:  Krisztian Elekes; Katalin Sandor; Andras Moricz; Laszlo Kereskai; Agnes Kemeny; Eva Szoke; Aniko Perkecz; Dora Reglodi; Hitoshi Hashimoto; Erika Pinter; Janos Szolcsanyi; Zsuzsanna Helyes
Journal:  Peptides       Date:  2011-05-14       Impact factor: 3.750

5.  Pituitary adenylate cyclase-activating polypeptide (PACAP) ameliorates experimental autoimmune encephalomyelitis by suppressing the functions of antigen presenting cells.

Authors:  Hideki Kato; Atsushi Ito; Jun Kawanokuchi; Shijie Jin; Tetsuya Mizuno; Kosei Ojika; Ryuzou Ueda; Akio Suzumura
Journal:  Mult Scler       Date:  2004-12       Impact factor: 6.312

6.  Mice deficient in neuropeptide PACAP demonstrate increased sensitivity to in vitro kidney hypoxia.

Authors:  G Horvath; B Racz; P Szakaly; P Kiss; E Laszlo; L Hau; A Tamas; Z Helyes; A Lubics; H Hashimoto; A Baba; D Reglodi
Journal:  Transplant Proc       Date:  2010 Jul-Aug       Impact factor: 1.066

7.  Pituitary adenylate cyclase-activating polypeptide attenuates streptozotocin-induced apoptotic death of RIN-m5F cells through regulation of Bcl-2 family protein mRNA expression.

Authors:  Satomi Onoue; Junko Hanato; Shizuo Yamada
Journal:  FEBS J       Date:  2008-11       Impact factor: 5.542

8.  Differential regulation of CXCL12 and PACAP mRNA expression after focal and global ischemia.

Authors:  Monika Riek-Burchardt; Angela Kolodziej; Petra Henrich-Noack; Klaus G Reymann; Volker Höllt; Ralf Stumm
Journal:  Neuropharmacology       Date:  2009-07-30       Impact factor: 5.250

9.  Pituitary adenylate cyclase-activating polypeptide is up-regulated in cortical pyramidal cells after focal ischemia and protects neurons from mild hypoxic/ischemic damage.

Authors:  Ralf Stumm; Angela Kolodziej; Vincent Prinz; Matthias Endres; Dai-Fei Wu; Volker Höllt
Journal:  J Neurochem       Date:  2007-09-14       Impact factor: 5.372

Review 10.  PACAP is implicated in the stress axes.

Authors:  Hitoshi Hashimoto; Norihito Shintani; Mamoru Tanida; Atsuko Hayata; Ryota Hashimoto; Akemichi Baba
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

View more
  50 in total

1.  Pituitary Adenylate Cyclase-Activating Polypeptide Is Upregulated in Murine Skin Inflammation and Mediates Transient Receptor Potential Vanilloid-1-Induced Neurogenic Edema.

Authors:  Zsuzsanna Helyes; Jozsef Kun; Nora Dobrosi; Katalin Sándor; Jozsef Németh; Aniko Perkecz; Erika Pintér; Krisztina Szabadfi; Balazs Gaszner; Valeria Tékus; Janos Szolcsányi; Martin Steinhoff; Hitoshi Hashimoto; Dora Reglődi; Tamas Bíró
Journal:  J Invest Dermatol       Date:  2015-04-23       Impact factor: 8.551

2.  PACAP protects against salsolinol-induced toxicity in dopaminergic SH-SY5Y cells: implication for Parkinson's disease.

Authors:  Dwayne Brown; Andrea Tamas; Dora Reglödi; Yousef Tizabi
Journal:  J Mol Neurosci       Date:  2013-04-28       Impact factor: 3.444

3.  PACAP enhances barrier properties of cerebral microvessels.

Authors:  Imola Wilhelm; Csilla Fazakas; Andrea Tamás; Gábor Tóth; Dóra Reglődi; István A Krizbai
Journal:  J Mol Neurosci       Date:  2014-03-11       Impact factor: 3.444

4.  Alteration of the PAC1 Receptor Expression in the Basal Ganglia of MPTP-Induced Parkinsonian Macaque Monkeys.

Authors:  M Feher; B Gaszner; A Tamas; A L Gil-Martinez; E Fernandez-Villalba; M T Herrero; D Reglodi
Journal:  Neurotox Res       Date:  2017-12-11       Impact factor: 3.911

5.  Protective Effect of PACAP on Ischemia/Reperfusion-Induced Kidney Injury of Male and Female Rats: Gender Differences.

Authors:  Eszter Laszlo; Tamas Juhasz; Adam Varga; Bernadett Czibere; Krisztina Kovacs; Peter Degrell; Gabriella Horvath; Gabor Jancso; Peter Szakaly; Andrea Tamas; Dora Reglodi
Journal:  J Mol Neurosci       Date:  2018-11-16       Impact factor: 3.444

6.  Structural and morphometric comparison of the molar teeth in pre-eruptive developmental stage of PACAP-deficient and wild-type mice.

Authors:  B Sandor; K Fintor; Sz Felszeghy; T Juhasz; D Reglodi; L Mark; P Kiss; A Jungling; B D Fulop; A D Nagy; H Hashimoto; R Zakany; A Nagy; A Tamas
Journal:  J Mol Neurosci       Date:  2014-08-12       Impact factor: 3.444

7.  Structural and Morphometric Comparison of Lower Incisors in PACAP-Deficient and Wild-Type Mice.

Authors:  B Sandor; K Fintor; D Reglodi; D B Fulop; Z Helyes; I Szanto; P Nagy; H Hashimoto; A Tamas
Journal:  J Mol Neurosci       Date:  2016-05-06       Impact factor: 3.444

8.  The Protective Role of PAC1-Receptor Agonist Maxadilan in BCCAO-Induced Retinal Degeneration.

Authors:  A Vaczy; D Reglodi; T Somoskeoy; K Kovacs; E Lokos; E Szabo; A Tamas; T Atlasz
Journal:  J Mol Neurosci       Date:  2016-08-26       Impact factor: 3.444

Review 9.  Current disease modifying approaches to treat Parkinson's disease.

Authors:  Dan Lindholm; Johanna Mäkelä; Valentina Di Liberto; Giuseppa Mudò; Natale Belluardo; Ove Eriksson; Mart Saarma
Journal:  Cell Mol Life Sci       Date:  2015-11-30       Impact factor: 9.261

10.  Pituitary Adenylate Cyclase Activating Polypeptide, A Potential Therapeutic Agent for Diabetic Retinopathy in Rats: Focus on the Vertical Information Processing Pathway.

Authors:  K Szabadfi; D Reglodi; A Szabo; B Szalontai; A Valasek; Gy Setalo; P Kiss; A Tamas; M Wilhelm; R Gabriel
Journal:  Neurotox Res       Date:  2016-01-06       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.